132 related articles for article (PubMed ID: 16227427)
21. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
Jois RN; Gaffney K; Keat A
Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
[No Abstract] [Full Text] [Related]
22. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
23. Switching anti-TNF therapy in ankylosing spondylitis.
Pradeep DJ; Keat AC; Gaffney K; Brooksby A; Leeder J; Harris C
Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
[No Abstract] [Full Text] [Related]
24. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
Hermann J; Müller T; Yazdani-Biuki B; Aringer M; Herold M; Ebner W; Ofner P; Graninger W
Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
[No Abstract] [Full Text] [Related]
25. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
[No Abstract] [Full Text] [Related]
26. Anti-TNF-associated palmoplantar pustulosis.
Pyrpasopoulou A; Chatzimichailidou S; Simoulidou E; Aslanidis S
J Clin Rheumatol; 2010 Apr; 16(3):138-9. PubMed ID: 20216329
[No Abstract] [Full Text] [Related]
27. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
[TBL] [Abstract][Full Text] [Related]
28. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
[TBL] [Abstract][Full Text] [Related]
29. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
30. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
31. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis--a drug side effect or uncontrolled systemic disease?
Edwards MH; Leak AM
Rheumatology (Oxford); 2009 Mar; 48(3):316-7. PubMed ID: 19106166
[No Abstract] [Full Text] [Related]
32. TNF inhibitors for ankylosing spondylitis in the real world.
McVeigh CM; Bell AL; Cairns AP
Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
[No Abstract] [Full Text] [Related]
33. The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.
Borman P; Ayhan F; Ceceli E
Rheumatol Int; 2010 Nov; 30(12):1689-90. PubMed ID: 20012962
[No Abstract] [Full Text] [Related]
34. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
35. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
Wendling D; Blagosklonov O; Streit G; Lehuédé G; Toussirot E; Cardot JC
Ann Rheum Dis; 2005 Nov; 64(11):1663-5. PubMed ID: 16227425
[No Abstract] [Full Text] [Related]
36. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
37. [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].
Toussirot E; Salard D; Algros MP; Aubin F
Ann Dermatol Venereol; 2013 Dec; 140(12):801-2. PubMed ID: 24315228
[No Abstract] [Full Text] [Related]
38. [Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
Dahl M; Ravn P
Ugeskr Laeger; 2005 Jan; 167(5):527-8. PubMed ID: 15745179
[No Abstract] [Full Text] [Related]
39. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
40. [A case of generalized tuberculosis in the use of infliximab (Remicade) in patients with Bekhterev's disease].
Nekrasov EV; Strelis AK; Ianova GV; Filiniuk OV; Buĭnova LN
Tuberk Biolezni Legkih; 2009; (8):56-60. PubMed ID: 19803353
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
